Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · VALIANT LABORATORIES LTD · 9 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
VALIANT LABORATORIES LTD is a listed company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY24–FY26 (all audited; no estimate years)
₹ crore · consolidated
FY24
FY25
FY26
Revenue
182
133
237
EBITDA (ex other income)
(8)
(5)
6
margin %
(4.6)
(3.5)
2.7
Owners' profit
0
(2)
(3)
EPS, as reported (₹)
0.13
(0.51)
(0.51)
ROE % · ROCE %
0.1 · (0.2)
(0.9) · (0.4)
(1.1) · 0.8
Debt / equity (x)
0.32
0.52
0.14
Cash from operations
2
1
(10)
Capex
(46)
(114)
(34)
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · VALIANT LABORATORIES LTD · 9 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
₹ crore
Q2 FY25
Q3 FY25
Q4 FY25
Q1 FY26
Q2 FY26
Q3 FY26
Q4 FY26
Q1 FY27
Revenue
21
35
58
47
46
52
92
115
Profit before tax
(4)
2
1
2
0
(3)
1
26
Net profit
(5)
2
1
2
0
(7)
2
21
EPS (₹)
(1.09)
0.54
0.16
0.42
0.04
(1.30)
0.32
3.89
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · VALIANT LABORATORIES LTD · 9 October 2026Page 3 of 3
Exhibit 3: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
1-day %
5-day %
29 Sept 2026 · Valiant Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
compliance
minimal
—
—
29 Sept 2026 · AGM 2026 voting results: all 18 resolutions passed with 99.6 percent plus approval
17 Sept 2026 · Board approves up to Rs 70 lakh investment in AMPYR for solar power supply
strategic transactions
high
—
—
17 Sept 2026 · Valiant Labs to invest up to Rs 70L in AMPYR Renewable Energy arm
strategic transactions
medium
—
—
4 Sept 2026 · Newspaper ad for dispatch of FY26 Annual Report and 5th AGM Notice
compliance
minimal
—
—
3 Sept 2026 · India Ratings assigns IND BBB Stable to Valiant Labs bank facilities
credit debt
medium
—
—
3 Sept 2026 · Annual Report FY25-26 web link sent to shareholders for 5th AGM
compliance
minimal
—
—
3 Sept 2026 · Notice of 5th AGM and Annual Report for FY 2025-26
board shareholder meetings
medium
—
—
3 Sept 2026 · Annual Report FY2025-26 and Notice of 5th AGM
results
high
—
—
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
